Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.7 (
acetylcholinesterase
)
28,390
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1 Cats were anaesthetized with pentobarbitone sodium and atropinized peripherally by intravenous injection of atropine methyl nitrate; the effect was examined of topical bilateral application of dyflos to the ventral surface of the medulla oblongata at a region lateral to the pyramids and caudal to the trapezoid bodies. Dyflos was applied by means of perspex rings; the volume of fluid placed in each ring was 10 mul.2 The topical application of dyflos (1-20 mg/ml) produced a fall in arterial blood pressure without changes in heart rate and, in experiments without artificial ventilation,
tachypnoea
with dissociation of thoracic and abdominal respiration.3 Atropine methyl nitrate (50 mg/ml) applied topically in the same way as dyflos, prevented or abolished its vasodepressor effect.4 The two reactivators of
acetylcholinesterase
, obidoxime (100-200 mg/ml) and pralidoxime mesylate (100-200 mg/ml), applied topically in the same way as dyflos, abolished its vasodepressor effect. The reactivator compound 30 (100 mg/ml), also a pyridinium aldoxime, did not have this effect.5 Obidoxime and pralidoxime mesylate also reversed the vasodepression produced by carbachol applied to the ventral surface of the brain stem but not the vasodepression produced by glycine similarly applied.6 The problem is discussed as to whether the reversal of the dyflos and carbachol-induced vasodepression by obidoxime and pralidoxime is due to
acetylcholinesterase
reactivation by dephosphorylation and decarbamylation respectively, to a central atropine-like action of these compounds or to a combination of both.
...
PMID:A central vasodepressor effect of Dyflos. 461 81
In vivo properties of pyrenebutyl-methylphosphonofluoridate (PBMPF) have been studied. The LD50 (i.v.) for mice was 15 mg/kg and toxic symptoms were typical of
cholinesterase
(ChE) inhibition but central signs were absent. After intraventricular injection of PBPMPF in unanaesthetized rabbits, continued walking in bizarre circular fashion together with peripheral vascular dilation and
tachypnoea
were observed. Recovery occurred 3 h post-injection. Fluorescent particles of unabsorbed material juxtaposed on lining ependyma were observed up to 14 days of administration. In addition, a large number of hippocampal cells showed vivid fluorescence, particularly in the cytoplasm, which was attributed to ChE inhibition. It is concluded that PBMPF seems promising as an organophosphate marker of nerve cells.
...
PMID:Pyrenebutyl-methylphosphonofluoridate: a fluorescent anti-cholinesterase in vivo. 657 41